Navigation Links
Novel Actemra monotherapy in treating patients with early aggressive rheumatoid arthritis

The first Phase III study involving the use of Actemra in the treatment of rheumatoid arthritis has revealed that it is superior to conventional treatment modality that uses disease modifying anti-rheumatic drugs (DMARDs to inhibit // joint destruction. It has also been found to provide symptomatic relief and improve sensation of pain.

Rheumatoid arthritis is a debilitating autoimmune disease in which the lining of the joints becomes inflamed causing irreversible joint damage and destruction. Actemra (tocilizumab) is a humanized anti-human interleukin-6 (IL-6) receptor monoclonal antibody. A monoclonal antibody is used to denote antibodies derived from genetically identical group of cells, a clone. The novel mechanism of action of the antibody can eventually pave way for a new therapeutic option for the treatment of RA. Nearly 306 patients with early aggressive rheumatoid patients were taken up for the study and were randomized to receive either Actemra as monotherapy or traditional treatment. Actemra was administered at 8 mg/kg I.V for every three weeks while the other group underwent treatment for 52 weeks. The administration of anti-TNF agents and leflunomide were restricted in the control group.

At the end of the study, the results were compared which revealed that there was a substantial reduction in the progression of joint damage over a 1-year period. Actemra was superior to DMARDs in preventing both erosion and joint space narrowing. Furthermore, the results are more promising in patients with early, aggressive disease.

The tolerability of the monotherapy was comparatively much higher in the Actemra group. Although there was a slight increase in the cholesterol level initially, it soon stabilized around the upper limit of normal. There was no incidence of tuberculosis in the group studied.

Similar clinical trials are being conducted in Europe and US to determine the efficacy and safety of Actemra in combinati on with other anti-rheumatoid medications. Head of Global Pharma Development, Roche, expressed his hope regarding the outcome of the clinical trials, expected to be released in the near future.
'"/>




Related medicine news :

1. Novel "CYCLOSPORINE CAPSULE FORMULATION" to be launched
2. Novel biopsy technique for prostate cancer
3. Novel computer model for breast cancer
4. Novel research on liver cancer
5. Novel way to fight cancer
6. Novel test for bowel cancer
7. Novel Anti-Neutrophilic Effect produced by Salmeterol in mild asthma patients
8. Novel Therapy for Chronic Problem
9. Blood Sugar Kept In Control By Novel Protein
10. Novel antibiotic dressing developed for improved wound healing
11. United Kingdom Is Lagging In Novelty In The Field Of Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/24/2017)... (PRWEB) , ... January 24, 2017 , ... ... solution provider of enterprise software products, today announced a strategic partnership with ... Blue users to access and analyze their Fusion platform for building powerful enterprise ...
(Date:1/24/2017)... California (PRWEB) , ... January 24, 2017 , ... i2i ... McNamara as chief financial officer. , “Cary’s broad financial background is ... possesses both the strategic planning and day-to-day financial operations skills we need to take ...
(Date:1/24/2017)... ... 24, 2017 , ... The Cruise Web Inc. was recognized today ... 4th Annual MSC True Partnerships’ Awards. , The 2016 MSC True Partnerships ... year based on overall business growth in revenue and guests and continuous partnership support ...
(Date:1/24/2017)... ... January 24, 2017 , ... Twelve startups have ... the 2017 Cupid's Cup Entrepreneurship Competition. Chaired by Under Armour Founder and CEO ... entrepreneurs will showcase their businesses on February 6, 2017, at Under Armour’s global ...
(Date:1/24/2017)... ... January 24, 2017 , ... West’s ... its annual Solutions Series of webinars will start January 31 with a session ... number of current health and benefits topics, including employee engagement, pricing transparency, population ...
Breaking Medicine News(10 mins):
(Date:1/24/2017)... , Jan. 24, 2017 Asia-Pacific Bone ... GlobalData,s new report, "Asia-Pacific Bone Densitometers Market Outlook ... Asia-Pacific Bone Densitometers market. The report provides value, ... and average prices (USD) within market segements - ... (QUS). The report also provides company shares ...
(Date:1/24/2017)... GREENVILLE, S.C. , Jan. 24, 2017 ... plans to release its fiscal 2017 first quarter results ... regular trading. The company will conduct a ... 3, to review the company,s financial and operating results for ... of the conference call will be available online at ...
(Date:1/24/2017)... , Jan. 24, 2017  In a ... Hospital Muenster, Germany 1 ... and FDA cleared NephroCheck® Test identified patients at ... open heart surgery. In this randomized control trial ... patients identified received either the institution,s standard of ...
Breaking Medicine Technology: